• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [216 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2026 National Institute for Health and Care Excellence (NICE) Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 1133
2026 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Addendum to Project A25-108]
2026 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (smouldering multiple myeloma) – Addendum to Project A25-109]
2026 Agency for Care Effectiveness (ACE) Talquetamab for relapsed or refractory multiple myeloma
2026 National Institute for Health and Care Excellence (NICE) Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 1149
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, suitable for autologous stem cell transplant) – Benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ciltacabtagene autoleucel (multiple myeloma, at least one prior therapy) – Benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma, first line, combination with bortezomib, lenalidomide and dexamethasone) – Benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ciltacabtagene autoleucel (multiple myeloma) – Addendum to Project A24-116]
2025 National Institute for Health and Care Excellence (NICE) Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal). NICE technology appraisal guidance 1084
2025 National Institute for Health and Care Excellence (NICE) Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable. NICE technology appraisal guidance 1098
2025 Center for Drug Evaluation (CDE) [HTA Rapid report-Elrexfio solution for injection (Relapsed or refractory multiple myeloma - RRMM)]
2025 Center for Drug Evaluation (CDE) [HTA Rapid report-Tecvayli (Relapsed or refractory multiple myeloma - RRMM)]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (newly diagnosed multiple myeloma, eligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2025 Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of elranatamab (Elrexfio)]
2025 National Institute for Health and Care Excellence (NICE) Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1114
2025 WorkSafeBC Industrial instrument mechanic and development of multiple myeloma
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linvoseltamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2025 Haute Autorite de sante (HAS) [Appropriateness of prescribing erythrocyte sedimentation rate (ESR) – are there any remaining?]
2024 Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal pharmacotherapy for transplant ineligible multiple myeloma
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elranatamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection acc. to the Law for More Safety in the Supply of Medicines (GSAV): talquetamab (multiple myeloma)]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for talquetamab (multiple myeloma) - First addendum to Project A23-100]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elranatamab (multiples Myelom) - Addendum zum Projekt A24-12]
2024 National Institute for Health and Care Excellence (NICE) Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 974
2024 National Institute for Health and Care Excellence (NICE) Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments. NICE technology appraisal guidance 970
2024 National Institute for Health and Care Excellence (NICE) Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 968
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Addendum to Project A24-35]
2024 National Institute for Health and Care Excellence (NICE) Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1015
2024 National Institute for Health and Care Excellence (NICE) Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1023
2023 Norwegian Institute of Public Health (NIPH) Treatments for relapsing and/or refractory multiple myeloma. A health technology assessment
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, = 1 prior therapy) - Addendum to Commission A22-100]
2023 Austrian Institute for Health Technology Assessment (AIHTA) [Update PET/PET-CT evidence for need based planning in the area of oncology]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ciltacabtagene autoleucel (multiple myeloma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: optical genome mapping - diagnosis and prognostic stratification of hematological malignancies]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teclistamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Talquetamab (multiple myeloma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ciltacabtagene autoleucel (relapsing/ refractory multiple myeloma, after at least 3 prior therapies)]
2023 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Belantamab mafodotin (reassessment after the deadline: multiple myeloma, at least 4 prior therapies, monotherapy)]
2023 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Talquetamab (multiple myeloma, at least 3 prior therapies)]
2023 National Institute for Health and Care Excellence (NICE) Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal). NICE technology appraisal guidance 869
2023 National Institute for Health and Care Excellence (NICE) Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. NICE technology appraisal guidance 870
2023 National Institute for Health and Care Excellence (NICE) Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 889
2023 National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 897
2023 National Institute for Health and Care Excellence (NICE) Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable. NICE technology appraisal guidance 917
2023 National Institute for Health and Care Excellence (NICE) Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal). NICE technology appraisal guidance 936
2022 Swiss Federal Office of Public Health (FOPH) Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma
2022 Austrian Institute for Health Technology Assessment (AIHTA) CAR-T cell-therapies in development, update 2022
2022 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ixazomib (reassessment after the deadline: multiple myeloma, at least 1 prior therapy, combination with lenalidomide and dexamethasone)]
2022 Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated multiple myeloma
2022 Agency for Care Effectiveness (ACE) Daratumumab-based regimens for newly diagnosed multiple myeloma
2022 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Idecabtagen vicleucel (multiple myeloma, at least 3 prior therapies)]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Addendum to Commission A21-101]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixazomib (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idecabtagene vicleucel (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Melphalan flufenamide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, fifth line) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V]
2022 National Institute for Health and Care Excellence (NICE) Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable. NICE technology appraisal guidance 763
2022 National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 771
2022 National Institute for Health and Care Excellence (NICE) Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 783
2022 National Institute for Health and Care Excellence (NICE) Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 841
2022 National Institute for Health and Care Excellence (NICE) Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment). NICE diagnostics guidance 47
2021 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Belantamab mafodotin (multiple myeloma, at least 4 prior therapies, monotherapy)]
2021 Institute for Clinical and Economic Review (ICER) Anti b-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma
2021 The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice isatuximab (Sarclisa®) for the treatment of multiple myeloma
2021 The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice multiple myeloma
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Addendum to Commission G20-22]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Addendum to Commission A21-08]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide and dexamethasone) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide and dexamethasone) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2021 National Institute for Health and Care Excellence (NICE) Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma. NICE technology appraisal guidance 680
2021 National Institute for Health and Care Excellence (NICE) Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma. NICE technology appraisal guidance 695
2021 National Institute for Health and Care Excellence (NICE) Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 700
2021 National Institute for Health and Care Excellence (NICE) Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 726
2021 National Institute for Health and Care Excellence (NICE) Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 727
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Addendum to Commission A19-80]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, stem cell transplant unsuitable) - Addendum to Commission A20-14]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, stem cell transplant suitable) - Addendum to Commission A20-15]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020 National Institute for Health and Care Excellence (NICE) Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 634
2020 National Institute for Health and Care Excellence (NICE) Carfilzomib for previously treated multiple myeloma. NICE technology appraisal guidance 657
2020 National Institute for Health and Care Excellence (NICE) Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 658
2019 NIHR Health Technology Assessment programme Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
2019 Adelaide Health Technology Assessment (AHTA) Immunoglobulin for acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT)